Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centre

Sorin, Mark; Camilleri-Broët, Sophie; Pichette, Emilie; Lorange, Justin-Pierre; Haghandish, Nasim; Dubé, Laurie-Rose; Lametti, André; Huynh, Caroline; Witkowski, Leora; Zogopoulos, George; Wang, Yifan; Wang, Hangjun; Spicer, Jonathan; Walsh, Logan A.; Rayes, Roni F.; Rouleau, Guy A.; Spatz, Alan; Corredor, Andrea Liliam Gomez; Fiset, Pierre‐Olivier

doi:10.1016/j.ctarc.2023.100696

Cited by 3 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particularly with regards to ALK and ROS1, which are found at rates of 1.5% and 0.3%, respectively, in data from Quebec and in 1-7% of patients with NSCLC in other studies [48,49], immunotherapy is not thought to be effective. In addition, routine PD-L1 tumor expression should be performed as the level of expression is related to drug efficacy in the context of neoadjuvant systemic immunotherapy and may impact individual treatment decisions.…”

Section: Staging and Diagnosismentioning

confidence: 90%

Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

Tankel,

Spicer,

Chu

et al. 2023

Current Oncology

Self Cite

View full text Add to dashboard Cite

The treatment paradigm for patients with stage II/III non-small-cell lung cancer (NSCLC) is rapidly evolving. We performed a modified Delphi process culminating at the Early-stage Lung cancer International eXpert Retreat (ELIXR23) meeting held in Montreal, Canada, in June 2023. Participants included medical and radiation oncologists, thoracic surgeons and pathologists from across Quebec. Statements relating to diagnosis and treatment paradigms in the preoperative, operative and postoperative time periods were generated and modified until all held a high level of consensus. These statements are aimed to help guide clinicians involved in the treatment of patients with stage II/III NSCLC.

show abstract

Section: Staging and Diagnosismentioning

confidence: 90%

Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

Tankel,

Spicer,

Chu

et al. 2023

Current Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, they found that actionable genetic alterations were significantly more frequent in never‐smokers (87.7%, p < 0.001), 22 as we have found in our study. Also, in study of Sorin et al 24 . it was described the genomic landscape of patients with lung cancer ( n = 997) with NGS in a Canadian hospital, founding a higher prevalence of KRAS mutations (39.2%) compared with most geographical locations, which proved the important to assess institutional rates of actionable driver mutations to help guide governing bodies 24 .…”

Section: Discussionmentioning

confidence: 99%

“…Also, in study of Sorin et al 24 . it was described the genomic landscape of patients with lung cancer ( n = 997) with NGS in a Canadian hospital, founding a higher prevalence of KRAS mutations (39.2%) compared with most geographical locations, which proved the important to assess institutional rates of actionable driver mutations to help guide governing bodies 24 . On the other hand, Garcia‐Casado et al 25 .…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, they found that actionable genetic alterations were significantly more frequent in neversmokers (87.7%, p < 0.001), 22 as we have found in our study. Also, in study of Sorin et al 24 it was described the genomic landscape of patients with lung cancer (n = 997) with NGS in a Canadian hospital, founding a higher prevalence of KRAS mutations (39.2%) compared with most geographical locations, which proved the important to assess institutional rates of actionable driver mutations to help guide governing bodies. 24 On the other hand, Garcia-Casado et al 25 and Sargas et al 26 are prospective studies of epithelial ovarian cancer and acute myeloid leukemia, respectively, that provide an extensive molecular characterization, risk stratification, ensuring technical quality and equity in access to NGS studies.…”

Section: Discussionmentioning

confidence: 99%

“…Also, in study of Sorin et al 24 it was described the genomic landscape of patients with lung cancer (n = 997) with NGS in a Canadian hospital, founding a higher prevalence of KRAS mutations (39.2%) compared with most geographical locations, which proved the important to assess institutional rates of actionable driver mutations to help guide governing bodies. 24 On the other hand, Garcia-Casado et al 25 and Sargas et al 26 are prospective studies of epithelial ovarian cancer and acute myeloid leukemia, respectively, that provide an extensive molecular characterization, risk stratification, ensuring technical quality and equity in access to NGS studies. 25,26 In non-European countries, the decision analytic model of Matsuda et al 27 that was used to estimate the budgetary impact of SSG testing versus NGS in newly diagnosed patients with advanced NSCLC in Japan, showing that the adoption of NGS instead of SSG would shorten the average turnaround time of testing (14.32 vs. 18.10, respectively).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Actionable mutational profiling in solid tumors using hybrid‐capture‐based next‐generation sequencing in a real‐world setting in Spain

Zazo,

Pérez‐Buira,

Carvajal

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

ObjectiveThis study aimed to describe the performance of a next‐generation sequencing (NGS) panel for the detection of precise genomic alterations in cancer in Spanish clinical practice. The impact of tumor characteristics was evaluated on informative NGS and actionable mutation rates.Materials and MethodsA cross‐sectional study was conducted at the Fundación Jiménez Díaz University Hospital (May 2021–March 2022) where molecular diagnostic of 537 Formalin‐Fixed Paraffin‐Embedded (FFPE) tissue samples of diverse solid tumors (lung, colorectal, melanoma, gastrointestinal stromal, among others) was performed using AVENIO Tumor Tissue Targeted Kit. A descriptive analysis of the features of all samples was carried out. Multivariable logistic analysis was conducted to assess the impact of sample characteristics on NGS performance defined by informative results rate (for all tumors and for lung tumors), and on actionable mutations rate (for lung tumors only).ResultsAVENIO performance rate was 75.2% in all tumor samples and 75.3% in lung cancer samples, and the multivariable analysis showed that surgical specimens are most likely to provide informative results than diagnostic biopsies. Regarding the mutational findings, 727 pathogenic, likely pathogenic, or variant of unknown significance mutations were found in all tumor samples. Single nucleotide variant was the most common genomic alteration, both for all tumor samples (85.3% and 81.9% for all solid tumors and lung samples, respectively). In lung tumors, multivariable analysis showed that it is more likely to find actionable mutations from non‐smokers and patients with adenocarcinoma, large cell, or undifferentiated histologies.ConclusionThis is the largest cohort‐level study in Spain to profile the analyses of biopsy samples of different tumors using NGS in routine clinical practice. Our findings showed that the use of NGS routinely provides good rates of informative results and can improve tumor characterization and identify a greater number of actionable mutations.

show abstract

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma

Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centre

Cited by 3 publications

References 30 publications

Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

Actionable mutational profiling in solid tumors using hybrid‐capture‐based next‐generation sequencing in a real‐world setting in Spain

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma

Contact Info

Product

Resources

About